The Clinical Effect and Mechanism of Kechuan Guben Pills for Blood Stasis Syndrome of COPD in Stable Stage

Objective: To observe the therapeutic efficacy and possible mechanism of Kechuan Guben Pills (KGP) in patients with blood stasis syndrome of COPD in stable stage. Methods: All patients diagnosed with blood stasis syndrome of COPD in stable stage hospitalized in Department of Respiratory and Critical Care Medicine, Linyi TCM Hospital from June 2021 to January 2023, were selected and randomly divided into control group received Budesonide 2 puffs, twice a day and treatment group given KGP on the basis of control group, 9 g, twice a day for six months. The traditional Chinese medicine (TCM) syndrome scores of patients were collected according to TCM Syndrome Diagnosis Criteria of Chronic Obstructive Pulmonary Diseaseand and the serum levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), high-sensitivity C-reactive protein (hs-CRP), transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF) were determined by immunofluorescence assay and latex enhanced immunoscattering turbidimetric assay. Results: The taotal effective rate of patients in the treatment group (96.97%) was significantly higher than that in the control group (82.86%), P P P Conclusion: KGP could significantly improve TCM symptoms of patients with blood stasis syndrome of COPD in stable stage by inhibiting the expressions of inflammatory factors and regulating the collagen fiber deposition related factors in the extracellular matrix.